Lexicon Pharmaceutcl (LXRX) 16.58 $LXRX 43.9% Return

New Post Public Reply Private Reply Replies (0) Message Board

Aug 1, 2016 at 12:18 PM

Lexicon Pharmaceutcl (LXRX) 16.58 $LXRX

43.9% Return Seen to Date on SmarTrend Lexicon Pharmaceuticals Call (LXRX)
Comtex SmarTrend(R) - Wed Jul 27, 12:57PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 5 months, Lexicon Pharmaceuticals has returned 43.87% as of today's recent price of $16.25.
LXRX: 16.58 (+0.26)

Lexicon Pharmaceuticals Shares Up 32.3% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Tue Jul 12, 1:28PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 32.27% as of today's recent price of $14.94.
LXRX: 16.58 (+0.26)

Lexicon Pharmaceuticals Shares Up 20.8% Since SmarTrend's Buy Recommendation (LXRX)
Comtex SmarTrend(R) - Thu Jun 16, 1:40PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 4 months, Lexicon Pharmaceuticals has returned 20.76% as of today's recent price of $13.64.
LXRX: 16.58 (+0.26)

Shares of LXRX Up 30.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 12:45AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 30.41% as of today's recent price of $14.73.
LXRX: 16.58 (+0.26)

Lexicon To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Mon Jun 06, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:30 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 16.58 (+0.26)

Premarket Research Report Covering the Biotech Industry
ACCESSWIRE - Mon Jun 06, 8:15AM CDT
LONDON, UK / ACCESSWIRE / June 6, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the biotech industry. Companies recently under review include Incyte, Chimerix, Lexicon Pharma, and Synthetic Biologics. Register with us now for your free membership and see our complete reports on these equities at:
SYN: 1.74 (-0.01), CMRX: 4.18 (+0.19), LXRX: 16.58 (+0.26), INCY: 91.23 (+1.02)

Lexicon Announces The Launch Of Aboutcarcinoid.com To Provide Carcinoid Syndrome Disease Education To Patients, Caregivers And Physicians
PR Newswire - Thu Jun 02, 3:15PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the launch of www.aboutcarcinoid.com to provide carcinoid syndrome disease education to patients, caregivers and physicians. Concurrent with the launching of the website, Lexicon is also working with seven leading national and regional patient advocacy groups to conduct the Carcinoid Syndrome Impact Survey, which is designed to improve understanding of the impact that carcinoid syndrome has on patient lives. Additional information on the survey can be found at www.aboutcarcinoid.com.
LXRX: 16.58 (+0.26)

Lexicon Pharmaceuticals Up 28.9% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Wed Jun 01, 1:24PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 28.91% as of today's recent price of $14.56.
LXRX: 16.58 (+0.26)

Lexicon Announces FDA Priority Review Of New Drug Application For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Tue May 31, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has granted a Priority Review of the NDA filing and set a Prescription Drug User Fee Act ("PDUFA"

target action date of November 30, 2016.
LXRX: 16.58 (+0.26)

Lexicon Pharmaceuticals Up 14.5% Since SmarTrend Uptrend Call (LXRX)
Comtex SmarTrend(R) - Wed May 25, 1:18AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 3 months, Lexicon Pharmaceuticals has returned 14.48% as of today's recent price of $12.93.
LXRX: 16.58 (+0.26)

Praveen Tyle, Ph.D. Joins Lexicon As Executive Vice President Of Research And Development
PR Newswire - Tue May 10, 7:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that Praveen Tyle, Ph.D. will join the company as its executive vice president of research and development, effective May 16, 2016, and will report to Lonnel Coats, Lexicon's president and chief executive officer. Dr. Tyle recently served as president, chief executive officer and board member of Osmotica Holdings and Osmotica Pharmaceutical.
LXRX: 16.58 (+0.26)

Lexicon reports 1Q loss
Automated Insights - Tue May 03, 6:20AM CDT
THE WOODLANDS, Texas (AP) _ Lexicon Pharmaceuticals Inc. (LXRX) on Tuesday reported a loss of $34.9 million in its first quarter.
LXRX: 16.58 (+0.26)

Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 First Quarter Financial Results
PR Newswire - Tue May 03, 6:00AM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2016 and provided an overview of key milestones for the company's lead drug candidates.
LXRX: 16.58 (+0.26)

Shares of LXRX Up 26.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 26, 12:56AM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 2 months, Lexicon Pharmaceuticals has returned 26.87% as of today's recent price of $14.33.
LXRX: 16.58 (+0.26)

Lexicon Pharmaceuticals Has Returned 24.8% Since SmarTrend Recommendation (LXRX)
Comtex SmarTrend(R) - Fri Apr 15, 1:38PM CDT
SmarTrend identified an Uptrend for Lexicon Pharmaceuticals (NASDAQ:LXRX) on March 2nd, 2016 at $11.30. In approximately 1 month, Lexicon Pharmaceuticals has returned 24.83% as of today's recent price of $14.10.
LXRX: 16.58 (+0.26)

Lexicon To Present At The 15th Annual Needham Healthcare Conference
PR Newswire - Thu Apr 07, 3:01PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 11:20 a.m. Eastern Time in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 16.58 (+0.26)

Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid Syndrome
PR Newswire - Wed Mar 30, 4:02PM CDT
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of telotristat etiprate, an oral drug for the treatment of carcinoid syndrome. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. Lexicon has requested a Priority Review by the FDA as part of the NDA filing.
LXRX: 16.58 (+0.26)

Lexicon To Present At The 36th Annual Cowen Healthcare Conference
PR Newswire - Thu Mar 03, 4:00PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 36th Annual Cowen Healthcare Conference on Wednesday, March 9, 2016 at 8:00 a.m. Eastern Time in Boston. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 16.58 (+0.26)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ace Hardware Ups the Stakes with Rewards Days Event

Ace Hardware: Doubling Down with Rewards Ace Hardware's rolling out the red carpet for its loyal customers. Imagine this: exclusive deals on trusted brands and double points on purchases—an incentive any savvy shopper would jump at. From October 6 to 7, those in the Ace Rewards circle have the chance to nab some hefty savings and perks, a move that's more than just a...

MiniCo's New Desk: A Game Changer for E&S Market

A New Chapter in Industrial Casualty Look out, folks! MiniCo Insurance Agency is making waves with its latest launch. They're teaming up with Lloyd's of London, not to sell fish and chips, but to bring something groundbreaking in the insurance space—an industrial casualty trading desk. And if you’re raising an eyebrow wondering why this matters, let me break it down...

Concrete Pipe: Foundation of Modern Infrastructure

Reinforced Concrete Pipes Hold Their Ground You know, it might not be the flashiest part of our infrastructure toolkit, but concrete pipe plays a mighty big role behind the scenes. Even in this age of shiny new tech and constantly evolving materials, the classic concrete pipe still packs a punch—especially when you demand something that'll last. Enter Stephanie Ward, a...

Maternal Health Index: A New Tool With Big Ambitions

A Fresh Take on Maternal Health Today's all about the Heartland Forward's fresh tool, the Maternal Resiliency Index. It's making a splash at the 2026 Heartland Summit with a lot of promise on its shoulders. Backed by economists and health gurus like Emily Oster and Dr. Neel Shah, this index ain't your run-of-the-mill tool. It's here to shake the couch coins out of...

Ultrabench Revolutionizes AI Model Comparison Game

Breaking Down the Messy AI Model Landscape Ultrabench.ai is here to drag AI model comparison out of the dark ages. Picture this: 309 AI models, ranked against a whopping 530 benchmarks, all served up on one plate. If you’re navigating the AI jungle, you’ll realize how Ultrabench is no small fish in this vast ocean. Consolidating Where Others Have Scattered There's a...

Cannatrol and Veterans Nonprofit Unite for Healing

Veterans Find a New Ally in Cannabis Tech When two distinct worlds collide for a cause, it can create waves of change much bigger than simple collaboration. That's exactly what's happening with Cannatrol and Operation Green Healing, a partnership that could redefine support for our veterans. Cannatrol, renowned for its groundbreaking post-harvest cannabis technology, has...

Athlete Threats: Public Info Fuels Security Risks

Public Exposure: The New Athlete Achilles' Heel Imagine sitting on millions while living in a glass house. That's the kind of predicament today's athletes find themselves in, thanks to the treasure trove of public information spilling their personal lives all over the internet. According to the latest Hush Intelligence Athlete Threat Report 2026, this very exposure has...

Haystack MRD Shines in Colorectal Cancer Trials

A New Dawn in Cancer Detection Just when you think you've seen it all in cancer diagnostics, Haystack MRD® pops up like a fresh tulip in spring. And listen, this ain't just fluff—the results from the DYNAMIC trials are a pretty compelling love letter to the power of liquid biopsy. With 100% specificity and sensitivity hitting a whopping 83.3% over five years, it’s...

Nukleus Launches Unified Platform for Athletes' Business

Leveling the Business Field for Athletes Athletes spend their lives fighting for every inch on the field, and now Nukleus is giving them the tools to hold ground off it. Why should they be the last ones to know their own business? Ashton Jeanty and Nukleus got tired of that narrative and kicked off a platform today with a real promise: putting an athlete's entire business...

Hyundai's Record Q3 Sales: SUVs and Hybrids Lead

Hyundai's Drive to Record Q3 Sales When talking about market moves, Hyundai's recent figures speak louder than most quarterly bells. September 2026 marked a whirlwind of growth for Hyundai Motor America, reporting record-breaking sales numbers not just for the month, but for Q3 as a whole. With a 9% jump from September last year in total vehicle sales and a remarkable 3%...